Treatment-related toxicity
tumor, pneumonia, TRAEs
DISEASE PROGRESSION, TUMOR, PNEUMONIA, ADVERSE EFFECT, PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, ADVERSE EFFECTS
Up until the cutoff date of December 15, 2022, the patients in the study received a median of 5 cycles of sintilimab treatment (range 1-24). The administration of sintilimab was generally well tolerated, as indicated by a total of 89.7% (26 out of 29) of patients experiencing at least one TRAE. The most frequently observed TRAEs are provided in Table Summary of sintilimab safety profileImmune-related adverse effects and infusion reactionsIn one case, a 14-year-old boy diagnosed with primary mediastinal large B-cell lymphoma experienced disease progression after completing six cycles of chemotherapy using the DA-R-EPOCH regimen. Subsequently, he received sintilimab treatment, and the best response obtained was SD, with the maximum diameter of the tumor reduced by 19%. However, after 5 courses of treatment, the patient developed a grade 1 adverse effect of immune pneumonia and voluntarily withdrew from the treatment (Supplementary Fig. 